Astec LifeSciences Limited announced its financial results for Q3 FY25, reporting a total income of 95.8 Crore, up 85.2% from 51.7 Crore in Q3 FY24, yet showing a consolidated EBITDA loss of 3.8 Crore, which is an improvement from a loss of 17.4 Crore in the previous year. However, for 9M FY25, the company saw a revenue decline to 266.6 Crore compared to 308.0 Crore in 9M FY24, and a significant net loss after tax of 118.6 Crore compared to 45.9 Crore in the previous year.